FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil steadies on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Five things to watch in markets in the week ahead
- Citi sees room for further equities upside in 2027 on resilient earnings growth
Coya Therapeutics completes enrollment in Phase 2/3 ALS trial
Tweet Send to a Friend
Coya Therapeutics, Inc. (NASDAQ: COYA) has completed enrollment of 120 participants in its Phase 2/3 ALSTARS trial evaluating COYA 302 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
